Cardiology

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he discusses upcoming advancements in heart failure care.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he walks through his long and successful career in cardiology.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

Ron Blankstein, MD, explains the value of PCD-CT and its consistency in both data collection and analysis of plaque with prior technology.

Hear Philip Adamson, MD, MSc, discuss his path through heart failure and his work with Abbott and CVRx.

Ann Marie Navar, MD, PhD, highlights enlicitide’s FDA approval for hypercholesterolemia and its potential to fundamentally change therapy.

Plozasiran cut triglycerides up to 81% and reduced acute pancreatitis events in phase 3 SHASTA-3, SHASTA-4 trials for severe hypertriglyceridemia.

Ron Blankstein, MD, discusses a recent study confirming the replicability of CCTA results with AI-CPA in patients with coronary plaque at risk of cardiovascular disease.

According to a recent study, nearly 32.2% of US adults are well above their LDL-C targets to avoid atherosclerotic cardiovascular disease.

After broadening eligibility criteria across several disease states and a wider age range, the new guidelines have made an estimated 87.5 million adults eligible for statins.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, phase 3 data, and open-label extension results.

Ron Blankstein, MD, discusses a secondary analysis of Heartflow’s DECIDE registry, indicating undetected cardiovascular risk in patients previously labeled safe.

Sanjay Rajagopalan, MD, discusses the need for more patient-specific air pollution warnings to optimize accessibility for all individuals.

Ann Marie Navar, MD, PhD, discusses the groundbreaking approval of the first oral PCSK9 inhibitor and what it means for patients managing their LDL-C levels.

A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.

A multidisciplinary clinical forum discussed diagnosis, referral thresholds, and the evolving APOC3-targeted treatment landscape for FCS.

Seth Martin, MD, MHS, discusses his recent study, which produced an AI-optimized equation that only requires 1 line of code.

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

These modifiable factors, among others, directly contribute to 88.7% of all IHD deaths in 2023.

Sripal Bangalore, MD, discusses his recent study proposing that early intervention can lead to better cardiovascular outcomes among these patients.

Jeffrey Weitz, MD, secretary general of the ISTH, discusses the recent analysis of the AXIOMATIC-TKR trial and its implications for FXIa inhibition.

Chiadi Ndumele, MD, PhD, breaks down the new guidelines and how they should be implemented in this sweeping document.

Parag Joshi, MD, highlights CAC scoring’s value as a prognostic tool for lipid-lowering therapy.

Richard Shi, MD, and Adam Tanious, MD, MBA, discuss the suboptimal number of patients at risk of long-term complications due to nonadherence.